Cortical Dynamics’ BARM Viz A Viz Global Market Competitors’ Systems

The Brain Anaesthesia Response Monitor (BARM) is an industry disruptive brain function monitor invented by an Australian based medical device technology company, Cortical Dynamics Limited. It is described as “a paradigm busting technology” that gives a significant competitive advantage in the medical technology space. At present, Cortical is focused towards the commercialisation of this patented technology which is invented by Prof. David Liley, co-founder of Cortical Dynamics.

BARM Addresses Significant Unmet Need in the Global Market

  • Unmet Need: It has been reported that 1 in 1000 patients wake up during surgery when administered with too little anaesthesia, a catastrophic event that may result in serious physical and psychological complication for patients. On the other hand, too much anaesthesia results in post-operative complications, such as extended stays in hospital, personal discomfort and distress and severe conditions like PTSD. 37-46% of surgical patients are affected by postoperative delirium rising to 87% depending on age & procedure
  • Changing patient profiles, an increase in risk of Delirium as more patients are older and obese.
  • Delirium cost to US Healthcare System estimated at $164Bn pa

The Solution:  Cortical’s break through system, BARM addresses these important unmet needs with their technology. Consequently aiding anaesthetists in maintaining an optimum dose of anaesthesia during major operations.

Advantages Over Global Market Competitors

The anaesthesia monitoring market comprises of 3 core players in addition to Cortical’s BARM System. While many EEG based monitors commercially available in the market at present, several well-documented limitations are associated with these monitors including-

  • inept monitoring of analgesic effects,
  • incapability to be sensitive to Ketamine, Nitrous Oxide and Opioids,
  • inability to measure the patient’s awareness Under anaesthesia.

The market across the globe, for surgical procedures including anesthesia is vast with the number of surgeries taking place annually being estimated to 312 million. With abundant market opportunity, Cortical’s BARM System fundamentally differentiate itself from the leading competitors BIS (Bispectral Index technology) from Medtronic and E-Entropy from GE via its innovative technology with distinct advantages in a significant global competitive market. 

Basis of Analysis

BARM’s mode of analysis involves an innovative way of EEG monitoring involving a specific real-time measurement of a patients’ brain’s rhythmic electrical activity recorded via electroencephalogram (EEG). It is the only monitor that uses fundamentally superior algorithms to current monitors derived from mathematical and physiological principles. While other anaesthesia monitoring systems in the market, BIS from Medtronic and E-Entropy from GE producestatistically based indices to characterize EEG not requiring physiological knowledge of how anaesthetic agents affect the brain.

Operational Features

Based on operational features, another advantage of BARM over its competitors including a quicker, response time of the data shown on the monitor. BARM takes 2 seconds of processing time to monitor and display a patients’ reading whereas the BIS monitor has a processing time of up to 30 seconds and E-entropy monitor takes somewhere between 39 seconds to 107 seconds to display reading.

Moreover, BARM is supposed to be the only EEG based monitor in the depth of anaesthesia monitors that measures both the hypnotic and analgesic state of patients by producing two unique indices while no other competitor can do so.

Utilising the CS and CI indices, it is observed that analgesia and anaesthesia may be potentially monitored independently, as indicated by the preliminary data. This independent monitoring of both anaesthesia and analgesia denotes a significant step onward in depth of anaesthesia monitors.

However, BIS and E-Entropy monitors cannot measure the level of analgesia (pain).

Detection of Analgesic Agents

Using a physiological based approach, BARM has shown greater sensitivity towards a range of sedative and anaesthetic agent including ketamine and nitrous oxide while the other leading depth of monitors are insensitive to these anaesthesia agents. BARM could also detect opiods while BIS and E-Entropy monitors cannot.

Besides, other applications of BARM have been identified on the basis of current EGG applications to date. These include:

  • Monitoring of Patients by well-trained staff in hospital wards, operating theatres or laboratories.
  • Neurodiagnostics, (monitoring changes in the brain and memory functions), to indicate early signs of degenerative diseases for hospital and research trials.
  • Tranquiliser and Pain response monitoring for hospitals & especially Trauma patients in Intensive Care Unit.
  • Drug discovery, drug evaluation and the developing Brain Computer Interface (BCI) market. 

BARM’s Key Expected Benefits

Cortical’s Versatile, Innovative Industry Disruptive Technology together with the advantages over its competitors is validated  by significant accomplishments including numerous awards and recognition achieved, extensive global patent coverage, clinical trials and regulatory approvals making Cortical stand out as a star amid competitive global brain monitoring and depth of anaesthesia markets. Moreover, the remarkable progress Cortical has made in the development of novel BARM system is supported by a robust and competent management team. 

Please click here for the offer document.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report